Ftse Mib
34.674,37
-0,25%
DAX
18.677,87
-0,45%
S&P 500
5.306,04
0,02%
NASDAQ
17.019,88
0,59%
Bitcoin
68.337,65
-1,52%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ HOOKIPA Pharma Inc (HOOK) HOOKIPA Pharma Inc (HOOK) Notizie

HOOK

HOOKIPA Pharma (HOOK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOOK
DataOraFonteTitoloSimboloCompagnia
23/05/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
23/05/202423:01GlobeNewswire Inc.HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingNASDAQ:HOOKHOOKIPA Pharma Inc
09/05/202413:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOOKHOOKIPA Pharma Inc
09/05/202413:01GlobeNewswire Inc.HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
25/04/202413:01GlobeNewswire Inc.HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabNASDAQ:HOOKHOOKIPA Pharma Inc
24/04/202413:01GlobeNewswire Inc.HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersNASDAQ:HOOKHOOKIPA Pharma Inc
16/04/202422:30GlobeNewswire Inc.HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:HOOKHOOKIPA Pharma Inc
10/04/202413:01GlobeNewswire Inc.HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationNASDAQ:HOOKHOOKIPA Pharma Inc
22/03/202412:01GlobeNewswire Inc.HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
06/03/202413:01GlobeNewswire Inc.HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:HOOKHOOKIPA Pharma Inc
29/01/202414:01GlobeNewswire Inc.HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership ProgramsNASDAQ:HOOKHOOKIPA Pharma Inc
16/01/202413:01GlobeNewswire Inc.HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationNASDAQ:HOOKHOOKIPA Pharma Inc
05/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:HOOKHOOKIPA Pharma Inc
22/12/202313:33Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HOOKHOOKIPA Pharma Inc
21/12/202313:01GlobeNewswire Inc.HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesNASDAQ:HOOKHOOKIPA Pharma Inc
20/11/202313:01GlobeNewswire Inc.HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusNASDAQ:HOOKHOOKIPA Pharma Inc
09/11/202313:01GlobeNewswire Inc.HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
03/11/202317:01GlobeNewswire Inc.HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023NASDAQ:HOOKHOOKIPA Pharma Inc
02/11/202321:01GlobeNewswire Inc.HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023NASDAQ:HOOKHOOKIPA Pharma Inc
22/10/202312:01GlobeNewswire Inc.HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023NASDAQ:HOOKHOOKIPA Pharma Inc
18/10/202313:01GlobeNewswire Inc.HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead SciencesNASDAQ:HOOKHOOKIPA Pharma Inc
13/09/202314:45GlobeNewswire Inc.HOOKIPA Announces Executive Leadership ChangeNASDAQ:HOOKHOOKIPA Pharma Inc
12/09/202314:01Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:HOOKHOOKIPA Pharma Inc
12/09/202313:01GlobeNewswire Inc.HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:HOOKHOOKIPA Pharma Inc
06/09/202313:01GlobeNewswire Inc.HOOKIPA Pharma to participate in upcoming investor conferences in SeptemberNASDAQ:HOOKHOOKIPA Pharma Inc
22/08/202322:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOOKHOOKIPA Pharma Inc
10/08/202322:13Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:HOOKHOOKIPA Pharma Inc
10/08/202313:01GlobeNewswire Inc.HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:HOOKHOOKIPA Pharma Inc
03/08/202313:01GlobeNewswire Inc.HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023NASDAQ:HOOKHOOKIPA Pharma Inc
10/06/202311:00GlobeNewswire Inc.HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:HOOKHOOKIPA Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOOK

La tua Cronologia

BOV
SGPS3M
SPRINGS ON
NYSE
RAX
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network